97P Asian Subgroup Analysis of the Phase III LEAP-017 Trial of Lenvatinib Plus Pembrolizumab Vs Standard-of-care in Previously Treated Metastatic Colorectal Cancer (Mcrc)

R-H. Xu,Zhangxin Chen,Hao-Wei Teng,Hongming Pan,Hui Zhong,Atsuo Takashima,T.-S. Yang,Y-M. Yeh,Yanhong Deng,T.W. Kim,Kim Ty,J.O. Park,M.A. Lee,Sang‐Cheol Lee,Kun‐Huei Yeh,Takayuki Yoshino,Roxana Fu,Rajeev Jain,David E. Adelberg,Akihito Kawazoe

DOI: https://doi.org/10.1016/j.annonc.2023.10.232

IF: 51.769

2023-01-01

Annals of Oncology

Abstract:In the global LEAP-017 trial, treatment with lenvatinib + pembrolizumab (L + P) trended toward longer, but not significant, OS (HR: 0.83, 95% CI: 0.68-1.02, p-value: 0.0379) vs regorafenib or trifluridine–tipiracil (SOC), and toward more benefit in PFS and ORR. We present results of an exploratory analysis of patients (pts) enrolled in Asia combined with an extension cohort from China. Eligible pts were aged ≥ 18 years, with confirmed unresectable, non-MSI-H/dMMR mCRC, and ≥1 prior line of therapy. Pts were allocated (1:1) to L (20 mg QD) + P (400 mg Q6W, up to 18 cycles) or SOC. Primary endpoint was OS. Secondary endpoints were PFS and ORR per RECIST 1.1 by BICR, and safety. At data cut-off (Feb 20, 2023), 237 pts were enrolled from Asia including China (N=100), Japan (N=63), Korea (N=41), and Taiwan (N=33). Overall, 118 pts received L + P, and 117 received SOC. In the Asia subgroup, after a median follow-up of 15.1 months (mo) and 15.2 mo, respectively, OS was longer with L + P vs SOC (median 13.4 vs 10.3 mo; HR: 0.63, 95% CI: 0.45-0.88), median PFS was 3.8 mo with L + P and 3.3 mo with SOC (HR: 0.78, 95% CI, 0.58-1.05), and ORR was 11.9% (95% CI, 6.6%- 19.1%) with L + P and 0% with SOC. In the China cohort, OS was longer with L + P vs SOC (median 14.9 vs 10.3 mo; HR: 0.61, 95% CI, 0.33-1.15), median PFS was 3.7 mo with L + P and 2.4 mo with SOC (HR: 1.18, 95% CI, 0.75-1.85), and ORR was 5.7% (95% CI, 1.2%-15.7%) with L + P and 0% with SOC. Grade ≥ 3 treatment-related AE rates were 58.5% and 49.6% with L + P and SOC, respectively, in the Asia subgroup, and 43.9% and 64.3%, respectively, in the Chinese extension cohort. One grade 5 treatment-related AE of pneumonitis occurred in the L + P arm in the Asia subgroup. In this exploratory analysis from the Asia subgroup of LEAP-017 including the China extension, treatment with L + P vs SOC trended toward longer OS, consistent with the global trial. Trends towards improved PFS and ORR with L + P were also seen, consistent with the global trial; however, a similar trend in the PFS HR in the China subgroup was not observed. No new safety signals were observed.